文献速递自身免疫性与大疱性皮肤病

天疱疮疾病面积指数最小临床重要差异的建立

Establishing minimal clinically important differences for the Pemphigus Disease Area Index.
PubMed 文献 · Br J Dermatol · 2024-01-01

该研究采用锚定法,以15点Likert量表和PGA-VAS为锚,在41例天疱疮患者(35例纳入分析)中计算PDAI的MCID。PDAI活动评分改善的MCID选定为2.65分(15点Likert锚,正确分类率78.7%),恶化的MCID为2.5分(两种锚一致)。这是首次确定PDAI的MCID,为临床试验和治疗评估提供基准。

要点

  • PDAI活动评分改善的MCID为2.65分(基于15点Likert锚)。
  • PDAI活动评分恶化的MCID为2.5分(15点Likert和PGA-VAS锚一致)。
  • 该MCID可用于天疱疮临床试验和治疗效果评估。

核心结论

  • 本研究首次确定PDAI评分改善和恶化的MCID,填补了该领域空白。
  • PDAI活动评分改善的MCID选定为2.65分,恶化的MCID为2.5分。

研究设计与样本

  • 研究招募41例天疱疮患者,其中35例符合MCID分析标准。
  • 采用锚定法,以15点Likert量表和PGA-VAS为锚计算MCID。
  • 使用ROC曲线确定最佳MCID切点(最高Youden指数)。

主要发现

  • 基于15点Likert锚,PDAI改善的MCID为2.65分(正确分类率78.7%,敏感度75.9%,特异度73.5%)。
  • 基于PGA-VAS锚,PDAI改善的MCID为2.5分(正确分类率78.0%,敏感度84.4%,特异度68.2%)。
  • 基于15点Likert锚,PDAI恶化的MCID为2.5分(正确分类率81.0%,敏感度72.7%,特异度81.0%)。
  • 基于PGA-VAS锚,PDAI恶化的MCID为2.5分(正确分类率70.9%,敏感度69.6%,特异度76.9%)。

关键数值与推荐

  • PDAI活动评分改善的MCID为2.65分(15点Likert锚)。
  • PDAI活动评分恶化的MCID为2.5分(15点Likert锚和PGA-VAS锚)。

临床怎么用

  • 临床中可用PDAI评分变化≥2.65分判断天疱疮病情改善。
  • PDAI评分增加≥2.5分提示病情恶化。
  • 该MCID可用于临床试验设计和治疗效果评估。

局限性

  • 研究样本量较小(41例招募,35例分析)。
  • MCID可能受文化差异影响,需国际协作验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Pemphigus is a rare autoimmune blistering disease with potentially life-threatening consequences. Establishing minimal clinically important differences (MCIDs) for disease severity scores like the Pemphigus Disease Area Index (PDAI) is crucial for assessing treatment efficacy. OBJECTIVES: To calculate MCIDs for both improvement and deterioration in PDAI scores in patients with pemphigus vulgaris (PV) and pemphigus foliaceus (PF), using the anchor-based method. METHODS: A total of 41 patients with pemphigus were recruited, with 35 meeting the MCID analysis criteria. The anchor-based method was used to calculate MCIDs for PDAI scores against the 15-point Likert scale and the Physician Global Assessment visual analogue scale (PGA-VAS) anchors. Receiver operating characteristic curves were employed to determine optimal MCID cutpoints with the highest Youden Index (J). The 15-point Likert scale scores the change in disease severity spanning from -7 to +7, designed to quantify the extent of disease improvement/deterioration since the preceding visit. RESULTS: The MCID for improvement in PDAI activity scores was 2.65 points using the 15-point Likert scale (78.7% correct classification; sensitivity 75.9%; specificity 73.5%) and 2.5 points using the PGA-VAS as the anchor (78.0% correct classification; sensitivity 84.4%; specificity 68.2%). Given the slightly higher correct classification rate using the 15-point Likert scale anchor, the MCID of 2.65 points was selected for PDAI activity score improvement. In contrast, the MCID for deterioration consistently remained at 2.5 points for the 15-point Likert scale anchor (81.0% correct classification; sensitivity 72.7%; specificity 81.0%) and 2.5 points for the PGA-VAS anchor (70.9% correct classification; sensitivity 69.6%; specificity 76.9%). CONCLUSIONS: This study marks the inaugural attempt at MCID determination for PDAI scores in pemphigus, filling a critical knowledge gap. The study's calculated MCIDs provide essential benchmarks for clinical trials, treatment evaluation and research design optimization. Future studies should explore international collaborations, to examine potential cross-cultural variations in MCIDs. Pemphigus is a rare and severe skin disease that causes painful blisters on the skin and mucous membranes. It affects about 1 to 5 people per million worldwide. In pemphigus, the immune system attacks the skin by mistake, leading to blisters that can be life-threatening if they get infected. In the past, the main treatment was steroids, which are effective, but they can have many side effects. Newer treatment options (with drugs such as rituximab) have reduced the risk of complications and relapses. The progress made in treating pemphigus has come from carrying out well-designed research studies. One important tool used to study pemphigus is the ‘Pemphigus Disease Area Index’ (or ‘PDAI’ for short). The PDAI helps doctors measure the severity of the disease. However, it has limitations and may not show small improvements that still matter to patients. This is where the ‘minimal clinically important difference’ (or ‘MCID’ for short) comes in. The MCID tells us how much change in PDAI scores is meaningful for patients. To date, there have been no studies published on MCIDs for the PDAI. This study, from Sydney, Australia, aimed to determine MCIDs for the PDAI. We studied 41 patients with pemphigus, 35 of whom were included in MCID analysis. The findings showed that a decrease of 2.65 points in PDAI scores means the disease is getting better. An increase of 2.5 points shows that the disease is getting worse. This information can help doctors and researchers understand if treatments are working and how they affect patients. Overall, our study findings are an important step towards improving care and treatments for people living with pemphigus.

来源:Br J Dermatol,查看原文。版权归原作者所有。

引用

  1. Tseng H, Stone C, Shulruf B, et al. Establishing minimal clinically important differences for the Pemphigus Disease Area Index. Br J Dermatol. 2024. PMID: 39001612. doi:10.1093/bjd/ljae283

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。